GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance
Cancer Care through Patient-Driven Insights

PR Newswire

ROCHESTER, N.Y. and PRINCETON, N.J., March 13, 2018

GRYT Health, a connected health start-up with a social purpose, and Bristol-Myers
Squibb Company (NYSE: BMY) today announced a strategic pilot utilizing
de-identified data to integrate patient insights and clinical research with
the goal of building a foundation of real-world data that will support
improved clinical trial design, disease management and the overall well-being
of patients living with cancer.

The pilot will provide Bristol-Myers Squibb with valuable insights from
patients on their experiences with cancer through GRYT’s app,
the most used patient and caregiver platform in oncology. The app is designed
to instantly and anonymously connect people affected by cancer with each
other, give them a platform for exchange and empower them with important
resources and information. By learning more about how patients experience and
manage their disease, Bristol-Myers Squibb and GRYT aim to accelerate health
innovations and improve quality of life for patients.

“This pilot represents a shared commitment between GRYT Health and
Bristol-Myers Squibb to improve the lives of patients through collaboration
and digital innovation,” said Dave Fuehrer, co-founder and CEO of GRYT Health.
“We worked with patients to build the GRYT app around their unique
preferences and expectations. Together with Bristol-Myers Squibb, we are
taking the same patient-driven approach to accelerate progress in the way we
manage disease and support the overall well-being for patients impacted by

“Our primary focus is always on the patient,” said Murdo Gordon, chief
commercial officer, Bristol-Myers Squibb. “Through our collaboration with
GRYT, we have the opportunity to incorporate the input of cancer patients
across our business – from research to patient support and empowerment
programs – that will best serve the cancer community.”

“Today’s technology has the potential to help us begin to close the gap
between patient experience and cancer research,” said Kate Owen, head of
clinical operations, Bristol-Myers Squibb. “Through the GRYT app, we
are excited to learn more from patients about how we can make our clinical
research programs as patient-friendly as possible.”

GRYT’s App is a free mobile app that provides instant, anonymous peer
support and targeted cancer information to anyone affected by cancer including
patients, survivors, caregivers, friends, family, medical professionals,
researchers and advocates. Users complete a short profile and are connected
with others based on the similarity of their experience. They can also
participate in moderated group chats and programs hosted by experts in their
field. GRYT’s App is available for free download for iOS devices and
for Android in April 2018.

At the 2018 SXSW Interactive Festival, GRYT Health was recognized as a
runner-up in the HealthSpark Barracuda Bowl, a “shark tank” like pitch
competition for innovative startups. GRYT was also selected as runner-up for
the Cambridge Healthtech Institute (CHI)’s 2018 Summit for Clinical Ops
Executives (SCOPE) award, recognizing innovation and change in how the
industry communicates with participants in the fields of recruitment and
retention in clinical trials.

About GRYT Health
GRYT Health is a Connected Health start-up with a social purpose. Founded in
2016 by cancer survivors and caregivers, GRYT developed the GRYT app,
a web-based mobile platform that is used in all 50 states and across 50
countries, to connect people with others just like them and with information
to manage their health on their terms. GRYT works with organizations who
specialize in oncology to ensure people have information and access to
options, so they can choose what’s right for them. GRYT is
headquartered in Rochester, NY. For more information, visit

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit or
follow us on Twitter at


Danielle Halstrom, 215-280-3898

Vikki Christian, 424-610-1241